Number of the records: 1
krizotinib
SYS d000077547 LBL 00000nz--a2200181n--4500 005 20250606222649.9 008 190101|||anznnbabn-----------|-a|a------ 040 $b slo $a BA006 $d BA006 065 $a D03.383.621.154 065 $a D03.383.725.050.263 066 $a 01 $c 03 150 $a krizotinib $x AA $x AD $x AE $x AG $x AI $x AN $x BL $x CF $x CH $x CL $x CS $x EC $x HI $x IM $x IP $x ME $x PD $x PK $x PO $x RE $x SD $x ST $x TO $x TU $x UR $2 slo 450 $w v $a Xalkori $2 slo 550 $7 sllk_us_auth*d000970 $Y Antineoplastic Agents $w P $a antineoplastiká 550 $7 sllk_us_auth*d000092004 $Y Tyrosine Kinase Inhibitors $w P $a inhibítory tyrozínkináz 665 $a 2019 (2010) $2 eng 680 9-
$i A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER. $2 eng 750 -2
$a Crizotinib $2 eng 980 $x M
Number of the records: 1